NCT01877629View on ClinicalTrials.gov

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2011

Primary Completion Date

July 1, 2011

Study Completion Date

July 1, 2011

Conditions
Healthy Subjects
Interventions
DRUG

ACT-129968 500 mg tablet

ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist

DRUG

ACT-129968 250 mg capsule

ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist

Trial Locations (1)

D-89081

PHAROS GmbH Clinical Research, Ulm

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT01877629 - Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects | Biotech Hunter | Biotech Hunter